Tekmira Pharmaceuticals Sees Significant Growth in Short Interest (TKMR)
Tekmira Pharmaceuticals (NASDAQ:TKMR) saw a significant increase in short interest during the month of August. As of August 15th, there was short interest totalling 2,689,028 shares, an increase of 279.0% from the July 31st total of 709,500 shares, AnalystRatingsNetwork.com reports. Approximately 13.4% of the shares of the company are sold short. Based on an average daily trading volume, of 9,723,707 shares, the days-to-cover ratio is presently 0.3 days.
A number of analysts have recently weighed in on TKMR shares. Analysts at Leerink Swann initiated coverage on shares of Tekmira Pharmaceuticals in a research note on Monday, August 18th. They set an “outperform” rating and a $25.00 price target on the stock. Separately, analysts at Maxim Group reiterated a “hold” rating on shares of Tekmira Pharmaceuticals in a research note on Friday, August 8th. They now have a $23.00 price target on the stock. Finally, analysts at Clarus Securities initiated coverage on shares of Tekmira Pharmaceuticals in a research note on Thursday, July 31st. They set a “buy” rating and a $22.50 price target on the stock. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $26.30.
Shares of Tekmira Pharmaceuticals (NASDAQ:TKMR) opened at 21.40 on Monday. Tekmira Pharmaceuticals has a 52 week low of $5.33 and a 52 week high of $31.48. The stock has a 50-day moving average of $14.76 and a 200-day moving average of $16.31.
Tekmira Pharmaceuticals (NASDAQ:TKMR) last issued its quarterly earnings data on Wednesday, August 13th. The company reported ($0.28) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.26) by $0.02. The company had revenue of $1.80 million for the quarter, compared to the consensus estimate of $3.72 million. Analysts expect that Tekmira Pharmaceuticals will post $-1.39 EPS for the current fiscal year.
Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on advancing ribonucleic acid (NASDAQ:TKMR) interference (RNAi) therapeutics and providing its lipid nanoparticle (LNP) delivery technology to pharmaceutical partners.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.